Latest news with #MESO
Business Insider
18-07-2025
- Business
- Business Insider
Mesoblast reports Q1 Ryoncil gross revenue $13.2M
Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is the first and only FDA approved mesenchymal stromal cell product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Chief Executive Dr. Silviu Itescu said, 'We are pleased with the commercial launch activities of Ryoncil in the first quarter post-launch and look forward to updating on the current quarter's progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major U.S. transplant centers.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Yahoo
26-02-2025
- Business
- Yahoo
Micro Enterprise Services of Oregon celebrates 20 years of empowering entrepreneurs
PORTLAND, Ore. (KOIN) — Micro Enterprise Services of Oregon is marking a major milestone after two decades of supporting small businesses and uplifting the local business community. MESO joins us on AM Extra to tell us how they are marking the anniversary and what the future holds for the organization. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
